A single AAV injection delivering a functional copy of the OTOF gene restored hearing in all ten patients enrolled in a clinical trial, according to results published in Nature Medicine. [1] Hearing gains appeared within one month and have been sustained. No batteries. No cochlear implant. No external device of any kind. Researchers used a modified adeno-associated virus to carry a functional copy of the gene directly to the inner ear, and the patients began to hear.

The therapy targets DFNB9, a rare form of genetic deafness caused by mutations in the OTOF gene — a condition that affects an estimated one to two percent of people born with congenital hearing loss. [2] That specificity is the caveat the viral posts omit. This is not a cure for deafness. It is a cure for one precisely defined genetic cause of deafness. But for the patients who carry that mutation, the result is as close to a complete medical reversal as the field has produced.

Congress is paying attention for a different reason. A congressional hearing on gene therapy regulation is running alongside the clinical results, with lawmakers weighing how the FDA should handle a category of treatment that rewrites the body's genetic instructions rather than managing symptoms. [2] The question is not whether gene therapy works — this trial answered that — but how fast the regulatory framework can adapt to a technology that makes permanent changes with a single dose. [1]

Ten for ten is a number that travels fast on social media and slowly through regulatory committees. Both speeds matter.

-- KENJI NAKAMURA, Tokyo